GenFleet Partners with BeiGene to Conduct P-Ib/II Trial of GFH009 and Brukinsa for the Treatment of Diffuse Large B Cell Lymphoma
Shots:
- GenFleet and BeiGene have signed a clinical trial collaboration and supply agreement to commence the P-Ib/II clinical evaluation of GFH009 (CDK9 inhibitor) + Brukinsa (BTK inhibitor) as a treatment of diffuse large B cell lymphoma (DLBCL)
- Under the collaboration, GenFleet will initiate the P-Ib/II study to assess the safety & efficacy of the combination for treating patients with r/r DLBCL and BeiGene will supply Brukinsa for the same
- Moreover, the company is investigating GFH009 for the treatment of peripheral T-cell lymphoma in China and acute myeloid leukemia across the US, the studies of which have been advanced to P-II
Ref: PR Newswire | Image: Sellas
Related News:- SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
